ARV-825 is a novel cereblon-based PROTAC (Proteolytic Targeted Chsimera) compound. It is a BRD4 inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, resulting in rapid, efficient and prolonged degradation of BRD4 and sustained downregulation of MYC. ARV-825 induces BRD4 protein degradation and downregulation of its targets, including c-Myc, Bcl-xL, and cyclin D1 in thyroid cancer cells. It was more potent than known small-molecule BRD4 inhibitors at inhibiting thyroid cancer cells.
ARV-825
| Cat# | Name | Structure | Pricing |
|---|---|---|---|
| AP14692 | ARV-825 | Pricing |
